*September 2025*
In this episode of LungCancerRx, Eric Singhi, MD, Aakash Desai, MD, MPH, and Fawzi F. Abu Rous, MD, welcome back Christine M. Lovly, MD, PhD, from Vanderbilt University, to talk about the complexities of treating advanced EGFR-positive non-small cell lung cancer. Dr. Lovely shares how she talks with patients about the latest data and recent trials, including FLAURA2 and MARIPOSA, and emphasizes the need to go beyond the efficacy numbers and weigh the “very different side effect costs” associated with the various treatments. With newer options available, she says that the question oncologists should ask themselves isn’t “Who needs a combination” but, rather, “Who doesn’t?”
